Pharma giant extends partnership with Cho Ray Hospital

The three-year agreement will focus on the implementation of clinical trials, workforce training, patient support programmes and further international integration of activities at Cho Ray Hospital. The collaboration will cover a variety of therapeutic areas such as oncology; respiratory and gastrointestinal diseases; cardiovascular and renal therapies; along with vaccines and immunology.

Nitin Kapoor, chairman and general director of AstraZeneca Vietnam and Asia Area Frontier Markets said, “AstraZeneca is dedicated to transforming outcomes for patients and increasing access to better healthcare for everyone. Furthering our collaboration with Cho Ray Hospital will expand the positive impact that we jointly make on local communities in Ho Chi Minh City and across the country.”

Dr. Nguyen Tri Thuc, director of Cho Ray added, “We are pleased to partner with AstraZeneca to accelerate our innovation and integration and deliver new programmes that increase patient access to innovative treatment. We will support colleagues in southern hospitals to develop their skills, so patients can receive the treatment they need in their hometowns.”

Cho Ray Hospital has played a key role in closing the gap between urban and rural hospitals through technology transfer, and cares for thousands of outpatients and inpatients each day.

This MoU is the latest milestone in an ongoing partnership between AstraZeneca and Cho Ray Hospital. So far, they have collaborated on the implementation of more than 30 clinical trials in different therapeutic areas and have joined forces for several scientific congresses, training programmes, and patient support initiatives.

AstraZeneca’s COVID-19 vaccine has been estimated to have prevented 232,766 deaths in Vietnam, according to an independent assessment of vaccine effectiveness conducted by Airfinity.

Last week marked an important step in AstraZeneca’s journey in Vietnam. On his visit to Hanoi, Dr. John L. Perez, senior vice president of the Vaccines and Immune Therapies Unit at AstraZeneca, talked to VIR’s Bich Thuy about the company’s future ambition and ongoing efforts to increase Vietnamese patients’ early access to new medicines.

The Medical Services Administration (MSA), under Vietnam’s Ministry of Health (MoH), and AstraZeneca Vietnam signed an MoU on September 20 to partner on the CaReMe – Love Yourself programme for the 2022-2025 period, aiming to enhance the quality of care for cardiovascular, renal, and metabolic diseases.

AstraZeneca Vietnam has been recognised as one of Vietnam’s top 100 best places to work in 2022, making it the fourth consecutive year that the company has won the recognition.

AstraZeneca Vietnam has received a certificate of merit from Prime Minister Pham Minh Chinh for the company’s exceptional contributions to Vietnam’s vaccine diplomacy efforts.